Aristotle University Of Thessaloniki (AUTH)
Συγκριτική μελέτη της επίδρασης της τελμισαρτάνης και της νεμπιβολόλης στην 24ωρη καταγραφή της αρτηριακής πίεσης και στη σκληρία των αρτηριών σε υπερτασικούς ασθενείς
Abstract
dc:descriptionEssential hypertension represents a major health problem concerning a large part of the population and regarding significant morbidity and mortality. In the natural course of the disease, lesions in the wall of arteries occur in response to increased pressure it receives. Vascular remodelling corresponding to increased blood pressure is called concentric and is characterized by increasing thickness of the vascular wall due to hypertrophy of the tunica media and fibrous thickening of the tunica intima.The vascular endothelium plays a crucial role in the process of vascular remodelling in the presence of hypertension. The basic endothelial vasoactive product that is of interest in the present study is nitric oxide (NO), a vasodilating molecule.The main objective of our study was to observe and compare changes in arterial stiffness due to long-term treatment with two antihypertensive drugs of different mechanisms of action. Changes in average pulse wave velocity of two study groups were studied: a group of hypertensive patients receiving telmisartan, a contemporary angiotensin receptor-blocker (ARB) and a group of hypertensive patients receiving nebivolol, a newer beta-blocker with an additive vasodilating action. The aim of the study was to observe and compare changes in pulse wave velocity during one year of treatment in both groups, independently of the corresponding BP fall.In our study, 129 consecutive patients who attended the Outpatient Hypertension-ABPM Clinic of the 3rd department of Internal Medicine were examined. Patients complained about random measurements of elevated BP. All cases regarded first diagnosis of hypertensive BP values, for which patients did not receive at the time of examination and had not previously received any antihypertensive medication.The final sample of the study comprised of 69 patients aged 20-73 years old, diagnosed with hypertension stage I (24h ambulatory SBP/DBP>130/80 mmHg), eligible for antihypertensive treatment. Patients whose ABP values were normalized after the three-month interval were excluded from randomization. Patients with “white-coat hypertension”, defined as elevated office BP values (SBP/DBP>140/90 mmHg) combined with normal ABP values (ambulatory SBP/DBP<130/80 mmHg) were also excluded from randomization.All participants in the study were randomized to receive either telmisartan 40 mg starting dose or nebivolol 5 mg starting dose. Patients of both groups received the above antihypertensive medication for 12 months’ time, during which they were re-examined with the use of ABPM and pulse wave velocity measurement at the end of the 1st, 6th and 12th month of treatment.After analysis and statistical processing of our sample, the results of our study are summarized as follows: Both telmisartan and nebivolol achieved comparable antihypertensive effects in terms of mean 24h-ABP and 24h daytime and nighttime BP, during 12 months of treatment. Telmisartan achieved in eliminating pulse wave velocity at a statistically significant level during the 12-month treatment period (p=0,006). This effect was independent of age, gender and mean 24h ABP values.Therefore it is concluded that administration of telmisartan in hypertensive patients who have not received any antihypertensive medication results in significant reductions in pulse wave velocity, independently of the beneficial effects in BP of patients.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papakatsika, Sofia
- Παπακάτσικα, Σοφία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40018